This study investigated the effects of NEAT1v1 on the sensitivity of liver cancer cell lines to sorafenib and lenvatinib and found that NEAT1v1 confers resistance to these drugs by activating AKT via superoxide dismutase 2 (SOD2) on the one hand, and NEAT1v1 concomitantly sensitizes cells to an AKT-targeted drug, capivasertib, on the other hand. This evidence concerns the gene AKT1 and liver cancer.